See our Downloads ▼ section to access our document – providing an overview of all guidance currently available for medical technology innovation opportunities and adoption. It will be updated monthly, please check back frequently.
This document will include:
- Novel Innovation is available via the Dynamic Purchasing System (DPS).
- NHSE MedTech Funding Mandate opportunities.
- Value Based Procurement (VBP).
- Novel Innovation and new areas to frameworks.
The guide is built to be used by a variety of roles, for example, procurement professionals, clinical specialists, project improvement leads, finance managers and innovation leads.
It will help you to build work plans at a time suitable to you, highlighting different types of benefits that can be realised, and opportunities for improvement in some of the more challenging areas of your work.
We will continue to support you with this process but have made this information available here to be accessed as and when you need it.
Take our five-minute survey about this page
We need to hear from you about how you are using this page and how useful the information is. Please complete our short survey to give us your feedback.
Download the latest document
Key features:
- Products are broken down into speciality areas, and patients in scope.
- Product description.
- Hyperlinks to NICE guidance, cost savings and case studies.
- Links to NHS Supply Chain VBP and case studies.
- Reference site details.
- NPC codes.
- Financial benefits.
- Operational benefits.
- Patient benefits.
- Environmental benefits.
- Key stakeholders.
- Health Innovation Network (HIN) Lead if MedTech Funding Mandate (MTFM).
- Additional resources.
- Contact details (in addition to your Hospital Care Team – ICS Managers).
New updates in April 2025
See our Downloads ▼ section to access the full document. Each month, we’ll provide a high-level summary of the latest updates.
Latest DPS and Innovations
Product Name: Genedrive
Point of care molecular testing to determine antibiotic treatment of early-onset neonatal infection, late-onset neonatal infection for example sepsis. Primarily used with neonates but could be used for renal, cystic fibrosis or with other patients eligible for aminoglycosides that require a fast or urgent response.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Advanced diagnostics genetics Obstetrics and gynaecology Paediatrics | Diagnostics prevention and health inequalities Maternity, neonatal and women’s health Quality and patient safety | Reduction in infection Reduce healthcare inequality Decreased appointment time Improved patient experiences Increased safety Faster diagnosis | Diagnostics prevention and health inequalities Maternity, neonatal and women’s health Quality and patient safety |
Product Name: Impella CPSA
The Impella device is a miniaturised, catheter-based, intravascular blood pump that supports a patient’s circulatory system. It provides continuous forward flow to increase overall cardiac output, end organ perfusion, unload work from the ventricle (decreasing myocardial oxygen demand) and improve coronary flow (increasing oxygen supply). This action is designed to support systemic haemodynamics and protect the myocardium from ischaemic damage. Impella can deliver 4.3 litres per minute of flow.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Interventional cardiology Cardiothoracic surgery Cardiac surgery Organ transplants | – | Faster recovery times Improved patient experiences Improved patient outcomes Reduced healthcare inequality | – |
Product Name: Quadsense
The Quadsense system, developed in the UK, balances the patellofemoral joint in knee surgery using a single-use sensor and a reusable panel.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Orthopaedics | Reducing elective care backlogs | Enhanced mobility and pain reduction Improved patient experiences Improved patient outcomes | Reduction in patient and visitor travel |
Product Name: Sonata system
The Sonata treatment (from Gynesonics) uses guided transcervical ultrasound and radiofrequency energy to shrink the fibroid and reduce symptoms without the need for any incisional intervention.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Obstetrics and gynaecology | Reducing elective care backlogs | Improved patient outcomes Reduction in pain | Reduction in patient and visitor travel |
For further details on these value-driving opportunities, please download the full Strategy Opportunity Document or contact:
DPS Customer Queries
MTFM : Apos Health
A non-invasive device for knee pain, improving mobility and deferring surgery with personalised treatment.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Orthopaedics | Reducing elective care backlogs | Better pre-operative health Cashable savings Cost avoidance Decreased waiting lists | Reduction in CO2 emissions Reduction in patient and visitor travel |
See our Useful Links section for details of your regional Care Pathway Team, who can conduct trust-specific financial modelling on this value-driving opportunity.
VBP : Cardiac Remote Monitoring
Real-time pacemaker data transmission, enhancing patient management and reducing clinic visits.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Administrative services Cardiology cardiovascular screening Clinical radiology Remote monitoring | Reducing elective care backlogs | Cost avoidance Improved patient experiences Operational efficiency Workforce efficiency | Reduction in CO2 emissions Reduction in patient and visitor travel |
See our Useful Links section for details of your regional Care Pathway Team, who can conduct trust-specific financial modelling on this value-driving opportunity.
Sustainability : Washable (single-patient reusable) Underwear
A range of washable (single-patient reusable) underwear for light to moderate urinary continence issues for adults and children.
| Areas of implementation and adoption | NHS Priorities | How does this improve the patient’s pathway? | Potential sustainability benefits |
| Acute Care Long-term Care Maternity Services Obstetrics and Gynaecology Postnatal Care Prostate Surgery Urology. | – | Patient empowerment | Reduction in CO2 emissions Reduction in product usage Reduction in waste |
For further details on this value-driving opportunity, please contact us.